Vicapsys Life Sciences, Inc.
Vicapsys Life Sciences, Inc. (VICP): 2 pipeline candidates · ~7 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
6.6 months
6% dilution
Lead: Preclinical
2 candidates
N/A
N/A
A transparent, data-derived signal for Vicapsys Life Sciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$47.3M
Cash
$90K
Quarterly Burn
$40K
Runway
6.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in Vicapsys Life Sciences, Inc.'s pipeline?
Vicapsys Life Sciences, Inc. (VICP) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Vicapsys Life Sciences, Inc.'s lead drug candidate?
Vicapsys Life Sciences, Inc.'s most advanced tracked candidate is vicapsyn (Preclinical) for Type 1 Diabetes (T1D).
What is Vicapsys Life Sciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Vicapsys Life Sciences, Inc. has approximately 6.6 months of cash runway.
What is Vicapsys Life Sciences, Inc.'s market capitalization?
Vicapsys Life Sciences, Inc.'s market capitalization is approximately $47.3M.
Who is the CEO of Vicapsys Life Sciences, Inc.?
Mr. Federico Pier is the chief executive officer of Vicapsys Life Sciences, Inc. (VICP).
Get the full picture on Vicapsys Life Sciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.